In early May, Novoheart had the opportunity to demo Miltenyi Biotec's UltraMicroscope Blaze – the light sheet microscope’s lightspeed mode allowed us to image multiple markers on entire engineered cardiac tissues in minutes. What an incredible tool for efficiently understanding both live and fixed tissue composition and structure. Thank you to Simon Merz, PhD and Rachel Roccanova, Ph.D., and the rest of the Miltenyi team who came onsite and made this such a valuable experience!
About us
Novoheart, a subsidiary wholly-owned by Medera (www.linkedin.com/company/medera-biopharmaceutical), is responsible for Disease Modelling & Drug Discovery using our proprietary award-winning mini-Heart Technology, which offers a range of bioengineered human heart constructs including the world’s first human heart-in-a-jar as healthy and diseased human hearts for testing toxicity and efficacy. This platform enables us to uniquely model human-specific diseases and discover therapeutic candidates all in the context of human cells and tissues, free from species-specific differences. Before privatisation by Medera, Novoheart was dually listed on the Toronto Stock Exchange and Frankfurt Stock Exchange.
- Website
-
https://www.novoheart.com
External link for Novoheart
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Boston, Massachusetts
- Type
- Privately Held
- Specialties
- Biotechnology, Drug Discovery, Stem Cell, Cardiovascular Safety, Drug Development, Cardiac Model, Human Disease Model, Medical Research, Research & Development, and BioEngineering
Locations
-
Primary
Get directions
6 Tide St, 2nd Floor
Boston, Massachusetts 02210, US
-
Get directions
Unit 810-813, 8/F, No. 15 Science Park West Avenue
Hong Kong Science Park
Hong Kong, HK
-
Get directions
1430-800 West Pender Street
Vancouver, British Columbia V6C 2V6, CA
Employees at Novoheart
Updates
-
Medera's CEO, Prof Ronald Li, and Sardocor's President, Prof Roger Hajjar were panel members at the CRIS discussion on Opportunities and Challenges in Investing in Cardiovascular and Cancer, Cell and Gene Therapy. #cardiovascular #cellandgenetherapy #heartdisease
#CardiovascularDiseases (CVD) are the leading cause of death globally, accounting for 17.9 million lives each year. In Singapore, heart disease is the leading cause of death, where on average, 34 people experience heart attacks and 23 people die from heart disease daily. With a rapidly ageing population and increases in cardiometabolic risk factors such as high blood pressure, obesity, and diabetes, these figures are projected to rise. In collaboration with Duke-NUS Medical School, SingHealth Duke-NUS Cardiovascular Sciences Academic Clinical Programme, Institute of Molecular and Cell Biology (IMCB), National Heart Centre Singapore, Mass General Brigham, Medera Inc., our programme, Cardiovascular Disease National Collaborative Enterprise (CADENCE), co-organised a half-day conference to discuss the latest technological advancements in the development of cell and gene therapies (CGT) for #CVD and #cancer. Keynote speakers Prof Joseph C. Wu, Director of the Stanford Cardiovascular Institute and President of the American Heart Association, and Prof Roger Hajjar, Director, Gene and Cell Therapy Institute at Mass General Brigham and Sardocor, spoke about the use of human cell models to screen potential new drugs and clinical trial to evaluate novel gene therapies for common and rare heart diseases. A panel consisting of A/Prof Danny Soon, CRIS CEO and Interim Executive Director of Advanced Cell Therapy and Research Institute, Singapore (ACTRIS), as well as, Dr Stephen Phua from Interpharma Investments, Dr Pei-Sze Ng 黄佩诗 from Leaps by Bayer, Prof Ronald Li from Medera, Prof Roger Hajjar from Sardocor and Dr Eugene Hong, MD from Healthcare & Pharmaceuticals, DBS Bank, also discussed the opportunities and challenges associated with investing in CGT treatments. The speakers acknowledged that risk management is critical to innovation. Hence, they stressed the need for a robust ecosystem helmed by key opinion leaders and strategic investors in key therapeutic areas who can come together to navigate those uncertainties, create change, and positively impact outcomes. Prof Derek Hausenloy, Executive Director of CADENCE, introduced the significance of the national clinical translational programme in synergising cardiovascular experts, research infrastructure, and technological capabilities across Singapore. He added, “We hope this will be a path forward to improving outcomes in patients with CVD, not just in Singapore but across the world.” Overall, it was an insightful afternoon as participants received a comprehensive overview of the state-of-the-art approaches in CGT as next-generation therapies for CVD and cancer, as well as expertise on opportunities and risks shared from medical, commercial and societal perspectives. Check out highlights from the event below! ✨ To find out more about CADENCE, visit https://lnkd.in/g-TzEyJu #hearthealth #cancerresearch #cellandgenetherapy #personalisedmedicine #regenerativemedicine
-
-
-
-
-
+4
-
-
Novoheart is excited to share that their bioengineered HFpEF Human mini-Heart models played a crucial role in Sardocor's ability to obtain Fast Track Designation for their investigational gene therapy treatment for HFpEF. Sardocor's clinical-grade AAV vector, SRD-001, was tested on both human ventricular Cardiac Tissue Strips #hvCTS and #hvCOC at Novoheart. Read the full press release here. https://lnkd.in/eeFzMbdD #heart #heartfailure #disease modeling
-
Contractile performance is an essential function of the human heart. 2-D cardiomyocyte cultures are inadequate for assessing contractility as they cannot perform physiological contractions on rigid plasticware. Novoheart’s human ventricular Cardiac Tissue Strip (hvCTS) offers a superior contractility assay. This assay consists of aligned hvCM in a 3-D hydrogel mixture that is constructed using a custom-designed cartridge with integrated force-sensing posts at the ends. This model has been validated as a sensitive and reliable predictor of clinical drug responses or pathologic effects on cardiac contractility. The CTScreen is Novoheart’s all-in-one screening system for comprehensive cardiac tissue contractility studies. Our unique system enables programmable force measurement protocols, including automated perfusion, electrical stimulation, data acquisition and streamlined data analysis. Customizable cartridges have been designed for the CTScreen to allow multiple tissues to be fabricated and cultured on each cartridge at the same time. All cartridges are compatible with Novoheart’s commercial CTScreen platform. #CTScreen #drugdiscovery #drugscreening #cardiac #3dcellculture #biotech #bioengineering
-
-
With the world’s first mini-Heart technology platform, Novoheart has previously partnered with AstraZeneca to construct the first HFpEF mini-Heart by molecular induction. The results have led to an ongoing FDA-approved First-In-Human Gene Therapy clinical trial in the United States. We proudly announce that Novoheart partners with National Heart Centre Singapore (NHCS) to create the world’s first Asian patient-specific miniature human heart model with heart failure, known as “Human Heart-in-a-Jar.” #Medera Inc #iPSC #mini-Heart #Novoheart #NHCS https://lnkd.in/g97Y-pdX
MEDERA’S NOVOHEART PARTNERS NATIONAL HEART CENTRE SINGAPORE TO DEVELOP ASIA’S FIRST BIOENGINEERED HUMAN HEART-IN-A-JAR
einpresswire.com